Biocon Biologics, Inc.

Biocon Biologics, Inc. is a subsidiary of Biocon Ltd., a publicly traded Indian biopharmaceutical company (BSE: 532523, NSE: BIOCON). Founded in 1978 and headquartered in Bengaluru, India, the parent company Biocon established Biocon Biologics as a separate entity in 2019 to focus on its biosimilars business. As a key subsidiary, Biocon Biologics is a significant contributor to Biocon Ltd.'s overall revenue, which was ₹16,470 crore (approximately $1.7 billion USD) for the fiscal year ending March 2025. Biocon Ltd. employs over 16,500 people.

Biocon Biologics is a fully integrated "pure play" biosimilars company, engaged in the development, manufacturing, and commercialization of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. Its portfolio includes a wide range of biosimilar molecules such as insulins, monoclonal antibodies, and recombinant proteins. Key commercialized products include biosimilars for Trastuzumab, Bevacizumab, Insulin Glargine, and Adalimumab. The company has a global footprint, with its products available in over 120 countries, and has established a direct commercial presence in the U.S. and Europe, notably after acquiring the biosimilars business of Viatris in 2022.

As an operating company focused on developing biosimilar products, Biocon Biologics' patent litigation posture is that of a plaintiff challenging existing patents held by originator pharmaceutical companies. The provided data shows one recent case as a plaintiff at the Patent Trial and Appeal Board (PTAB), which is consistent with the business model of a biosimilar developer seeking to invalidate patents to enable market entry. This type of litigation is a common feature of the biosimilar industry, where companies proactively challenge the validity of patents on branded biologic drugs they aim to compete with.

The single tracked case, Biocon Biologics, Inc. et al. v. Regeneron Pharmaceuticals, Inc., is part of a larger, multi-party dispute over patents for Regeneron's blockbuster eye drug, Eylea (aflibercept). Biocon, along with other biosimilar developers, has been engaged in litigation, including inter partes reviews (IPRs) at the PTAB, to challenge the validity of Regeneron's patents. In April 2025, Biocon and its partner Mylan reached a settlement with Regeneron, resolving the litigation and clearing a pathway for Biocon to launch its aflibercept biosimilar, YESAFILI, in the United States. This case highlights the company's strategy of using the patent system's challenge mechanisms to bring its biosimilar products to market.